Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

According to Trace One, when factoring in eating habits, food insecurity rates, alcohol consumption, and the prevalence of ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...

The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January ...